Jagan still sees a Fresenius issue. I am still waiting for Jagan's purported Takeda buyout of "only a matter of days" he pumped last August. Read the following excerpt from an reported Omontys anaphylaxis analysis and see if you spot the Fresenius issue as does Jagan:
"The cases were reported by different dialysis centres. One centre reported 3 SAEs, another reported 2 SAEs, and the remaining 18 SAEs were reported each by a different dialysis centre. The 5 fatal cases were reported by 5 different dialysis centres....
Of major concern is the question whether these serious hypersensitivity reactions can be adequately managed. It should be noted that patients have all received Omontys within a well-controlled clinical environment, where adequate treatment was available (e.g. IV antihistamines, steroids and adrenaline) and presumably timely given, which however did not prevent life-threatening situations or fatal outcomes. Of note is also the very fast course of the events (for the fatal cases, patients had a cardiopulmonary arrest within 5-10 minutes of Omontys administration), which could also explain the poor outcomes despite availability of timely medical treatment."
What a blockbuster drug, especially compared to industry standard ESAs of many years use with well established patient safety profiles. The doctors are anxious to kill their patients with O. After all, these CKD dialysis patients are very ill already.